polly,
I'm sure you're right on that account. But as we have seen, be it Teva or WPI, the earnings won't even move their needle.
I don't think this was ever a Teva item at all, but more of an anti-Momenta item. I haven't heard one peep out of Teva or any analyst regarding Teva's application since Amphastar was approved.